Valuation: Evelo Biosciences, Inc.

Market Cap 11.66L 10.2L 9L 9L 16.49L 11Cr 16.77L 1.12Cr 44.16L 5.48Cr 43.8L 42.85L 19Cr P/E 2021
-2.63x
P/E 2022 -1.23x
Enterprise Value 43.64L 38.18L 35.21L 32.52L 61.71L 42Cr 62.75L 4.21Cr 1.65Cr 21Cr 1.64Cr 1.6Cr 70Cr EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day+9,900.00%
1 month-66.67%
6 months-80.00%
Current year-80.00%
1 week 0
Extreme 0
0
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
13.93
5 years 0
Extreme 0
275.4
10 years 0
Extreme 0
398.57
Manager TitleAgeSince
Chief Executive Officer 64 21/11/2023
Director TitleAgeSince
Director/Board Member 64 21/11/2023
Date Insider Type Main position Quantity % Market Cap.
07/23/07Fiscal year

Chief Executive Officer

2,516 0.0134%
07/23/07Fiscal year

Chief Financial Officer

14,811 0.0786%
07/23/07Fiscal year

Chief Technology Officer

16,413 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
+9,900.00%0.00%-80.00%-100.00% 1.9T
+1.84%-0.66%+59.82%+92.96% 5.49TCr
-4.14%-8.06%+58.96%+118.67% 5.46TCr
-2.24%+3.59%+17.75%+477.47% 2.51TCr
-1.60%-6.21%-18.96%-15.21% 2.31TCr
+2.43%+1.06%+42.44%-1.27% 1.99TCr
-3.19%0.00%+35.60%-26.98% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+51.91%+726.40% 1.57TCr
-1.05%+1.16%+25.95%+194.27% 1.42TCr
Average +989.40%-0.25%+38.86%+182.35% 2.42TCr
Weighted average by Cap. -0.89%-1.45%+51.26%+177.14%

Financials

2021 2022
Net sales - -
Net income -12Cr -11Cr -9.86Cr -9.1Cr -17Cr -1.17TCr -18Cr -117.78Cr -46Cr -574.04Cr -46Cr -45Cr -1.97TCr -11Cr -10Cr -9.24Cr -8.53Cr -16Cr -1.09TCr -16Cr -110.4Cr -43Cr -538.1Cr -43Cr -42Cr -1.85TCr
Net Debt -1.21Cr -1.06Cr -98.01L -90.52L -1.72Cr -115.86Cr -1.75Cr -12Cr -4.6Cr -57Cr -4.56Cr -4.46Cr -196.22Cr 31.98L 27.97L 25.8L 23.83L 45.22L 31Cr 45.98L 3.08Cr 1.21Cr 15Cr 1.2Cr 1.17Cr 52Cr
Logo Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Employees
66
Date Price Change Volume
08/26/08 $0.000100 +9,900.00% 1,049
  1. Stock Market
  2. Stocks
  3. EVLO Stock